- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06568939
Un estudio para evaluar los eventos adversos y cómo el Telisotuzumab Vedotin (ABBV-399) infundido por vía intravenosa (IV) se mueve a través del cuerpo como monoterapia en participantes adultos con cáncer de pulmón de células no pequeñas (NSCLC) no escamoso previamente tratado
Un estudio global de fase 2, abierto, aleatorizado, de dos regímenes de telisotuzumab vedotina en sujetos con cáncer de pulmón de células no pequeñas, no escamoso, localmente avanzado/metastásico, de tipo salvaje EGFR, sobreexpresión de c-Met, previamente tratado
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult participants with NSCLC. Change in disease activity and adverse events will be assessed.
Telisotuzumab vedotin is an investigational drug being developed for the treatment of NSCLC. Participants will be randomly assigned a treatment of telisotuzumab vedotin in 1 of 3 arms at an 1:1:1 ratio. Each group receives intravenous (IV) infusion of telisotuzumab vedotin at different doses. Approximately 150 adult participants with c-Met overexpressing NSCLC will be enrolled in the study at approximately 80 to 90 sites worldwide.
Participants will receive IV telisotuzumab vedotin at 1 of 3 dose regimens as part of a 3 year study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: ABBVIE CALL CENTER
- Número de teléfono: 844-663-3742
- Correo electrónico: abbvieclinicaltrials@abbvie.com
Ubicaciones de estudio
-
-
-
São Paulo, Brasil, 01323-020
- Reclutamiento
- Hospital Alemao Oswaldo Cruz - Sao Paulo /ID# 272512
-
-
Ceará
-
Fortaleza, Ceará, Brasil, 60810-180
- Reclutamiento
- Suporte Nutricional e Quimioterapia LTDA - PRONUTRIR /ID# 273203
-
-
Paraná
-
Curitiba, Paraná, Brasil, 80510-130
- Reclutamiento
- Ictrials Pesquisa E Desenvolvimento /ID# 276681
-
-
Pará
-
Belém, Pará, Brasil, 66063-495
- Reclutamiento
- Cto - Centro De Tratamento Oncologico /ID# 276699
-
-
Pernambuco
-
Recife, Pernambuco, Brasil, 50040-000
- Reclutamiento
- Hospital De Cancer De Pernambuco /ID# 276104
-
-
Rio Grande do Norte
-
Natal, Rio Grande do Norte, Brasil, 59075-740
- Reclutamiento
- Liga Norte Riograndense Contra O Cancer /ID# 273183
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Brasil, 98700-000
- Reclutamiento
- Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 272513
-
-
Santa Catarina
-
Florianópolis, Santa Catarina, Brasil, 88020-210
- Reclutamiento
- Cepen - Centro De Pesquisa E Ensino Em Oncologia De Santa Catarina /ID# 273204
-
-
-
-
Arizona
-
Chandler, Arizona, Estados Unidos, 85224
- Reclutamiento
- Ironwood Cancer and Research Center /ID# 276370
-
-
Arkansas
-
Little Rock, Arkansas, Estados Unidos, 72205
- Reclutamiento
- University of Arkansas for Medical Sciences /ID# 272923
-
-
California
-
Los Angeles, California, Estados Unidos, 90067
- Reclutamiento
- Valkyrie Clinical Trials /ID# 271322
-
Los Angeles, California, Estados Unidos, 90025
- Reclutamiento
- Start Los Angeles /ID# 284999
-
Oxnard, California, Estados Unidos, 93030
- Reclutamiento
- FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 284816
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06510
- Terminado
- Yale New Haven Hospital /ID# 271584
-
-
Florida
-
Jacksonville, Florida, Estados Unidos, 32256
- Reclutamiento
- Cancer Specialists of North Florida - Jacksonville - AC Skinner Parkway /ID# 270899
-
Ocala, Florida, Estados Unidos, 34474
- Reclutamiento
- Ocala Oncology Center /ID# 273697
-
Pembroke Pines, Florida, Estados Unidos, 33028
- Reclutamiento
- Memorial Hospital West /ID# 270313
-
St. Petersburg, Florida, Estados Unidos, 33701-4732
- Reclutamiento
- Comprehensive Hematology Oncology /ID# 270422
-
St. Petersburg, Florida, Estados Unidos, 33705
- Reclutamiento
- Florida Cancer Specialists - North /ID# 271995
-
West Palm Beach, Florida, Estados Unidos, 33401
- Reclutamiento
- Florida Cancer Specialists - East /ID# 271993
-
-
Georgia
-
Athens, Georgia, Estados Unidos, 30607
- Reclutamiento
- University Cancer and Blood Center /ID# 270969
-
Marietta, Georgia, Estados Unidos, 30060
- Reclutamiento
- Northwest Georgia Oncology Centers /ID# 275374
-
Savannah, Georgia, Estados Unidos, 31404
- Terminado
- Memorial University Medical Center /ID# 272467
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96819
- Reclutamiento
- Kaiser Permanente Moanalua Medical Center /ID# 272916
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60607
- Reclutamiento
- University of Illinois Hospital and Health Sciences System /ID# 275345
-
Niles, Illinois, Estados Unidos, 60714
- Reclutamiento
- Illinois Cancer Specialists /ID# 274678
-
Peoria, Illinois, Estados Unidos, 61637-0001
- Reclutamiento
- OSF St. Francis Medical Center /ID# 281591
-
Springfield, Illinois, Estados Unidos, 62702
- Reclutamiento
- Springfield Clinic - First /ID# 272576
-
-
Nebraska
-
Lincoln, Nebraska, Estados Unidos, 68506
- Reclutamiento
- Nebraska Hematology-Oncology /ID# 272970
-
Omaha, Nebraska, Estados Unidos, 68130
- Reclutamiento
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271527
-
-
Nevada
-
Reno, Nevada, Estados Unidos, 89502
- Reclutamiento
- Renown Regional Medical Center /ID# 273535
-
-
New Jersey
-
East Brunswick, New Jersey, Estados Unidos, 08816-4096
- Reclutamiento
- Astera Cancer Care /ID# 272359
-
Teaneck, New Jersey, Estados Unidos, 07666
- Reclutamiento
- Regional Cancer Care Associates /ID# 270783
-
-
New York
-
The Bronx, New York, Estados Unidos, 10461
- Reclutamiento
- Montefiore Medical Center - Einstein Campus /ID# 277169
-
Westbury, New York, Estados Unidos, 11590
- Reclutamiento
- Clinical Research Alliance (SMO/Network/Consortium) /ID# 270455
-
-
North Carolina
-
Pinehurst, North Carolina, Estados Unidos, 28374
- Reclutamiento
- FirstHealth of the Carolinas- Speciality Center /ID# 272924
-
-
Ohio
-
Perrysburg, Ohio, Estados Unidos, 43551
- Reclutamiento
- Mercy Health - Perrysburg Cancer Center /ID# 270536
-
Zanesville, Ohio, Estados Unidos, 43701
- Reclutamiento
- Genesis Healthcare System /ID# 273361
-
-
Pennsylvania
-
Sayre, Pennsylvania, Estados Unidos, 18840
- Reclutamiento
- Guthrie Robert Packer Hospital /ID# 270316
-
York, Pennsylvania, Estados Unidos, 17403
- Reclutamiento
- Cancer Care Associates Of York /ID# 270971
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Reclutamiento
- Medical University of South Carolina /ID# 273272
-
Greenville, South Carolina, Estados Unidos, 29607
- Reclutamiento
- Saint Francis Cancer Center - Greenville /ID# 276368
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- SCRI Oncology Partners /ID# 270162
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75246
- Reclutamiento
- Texas Oncology - Dallas - Worth Street /ID# 278947
-
Tyler, Texas, Estados Unidos, 75702
- Reclutamiento
- Texas Oncology - Northeast Texas /ID# 272000
-
-
Utah
-
Ogden, Utah, Estados Unidos, 84405
- Reclutamiento
- Community Cancer Trials Of Utah /ID# 276598
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Reclutamiento
- Virginia Cancer Specialists - Fairfax /ID# 272004
-
-
Washington
-
Spokane, Washington, Estados Unidos, 99208
- Reclutamiento
- Medical Oncology Associates - Spokane /ID# 277172
-
Tacoma, Washington, Estados Unidos, 98405
- Reclutamiento
- Northwest Medical Specialties Tacoma /ID# 270534
-
-
-
-
-
Haifa, Israel, 3109601
- Reclutamiento
- Rambam Health Care Campus- Haifa /ID# 270078
-
Jerusalem, Israel, 9103102
- Terminado
- Shaare Zedek Medical Center /ID# 270095
-
-
Central District
-
Kefar Sava, Central District, Israel, 4428164
- Reclutamiento
- Meir Medical Center /ID# 270071
-
Petah Tikva, Central District, Israel, 4941492
- Reclutamiento
- Rabin Medical Center. /ID# 270087
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, Israel, 5265601
- Reclutamiento
- The Chaim Sheba Medical Center /ID# 270068
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japón, 466-8560
- Reclutamiento
- Nagoya University Hospital /ID# 277010
-
-
Chiba
-
Kashiwa-shi, Chiba, Japón, 277-8577
- Reclutamiento
- National Cancer Center Hospital East /ID# 277056
-
-
Hokkaido
-
Sapporo, Hokkaido, Japón, 060-8648
- Reclutamiento
- Hokkaido University Hospital /ID# 277014
-
-
Hyōgo
-
Kobe, Hyōgo, Japón, 650-0046
- Reclutamiento
- Kobe Minimally Invasive Cancer Center /ID# 277469
-
-
Kanagawa
-
Sagamihara-shi, Kanagawa, Japón, 252-0375
- Reclutamiento
- Kitasato University Hospital /ID# 277012
-
-
Miyagi
-
Sendai, Miyagi, Japón, 981-0914
- Reclutamiento
- Sendai Kousei Hospital /ID# 277023
-
-
Miyazaki
-
Miyazaki, Miyazaki, Japón, 889-1692
- Reclutamiento
- University of Miyazaki Hospital /ID# 277020
-
-
Okayama-ken
-
Kurashiki-shi, Okayama-ken, Japón, 710-8602
- Reclutamiento
- Kurashiki Central Hospital /ID# 276995
-
-
Shizuoka
-
Fujieda, Shizuoka, Japón, 426-0077
- Reclutamiento
- Fujieda Municipal General Hospital /ID# 277025
-
-
Wakayama
-
Wakayama, Wakayama, Japón, 641-8510
- Reclutamiento
- Wakayama Medical University Hospital /ID# 276997
-
-
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, Porcelana, 101149
- Reclutamiento
- Beijing Chest Tumor Hospital /ID# 271935
-
-
Fujian
-
Fuzhou, Fujian, Porcelana, 350014
- Reclutamiento
- Fujian Province Cancer Hospital /ID# 276178
-
-
Guangxi
-
Nanning, Guangxi, Porcelana, 530021
- Reclutamiento
- Affiliated Cancer Hospital of Guangxi Medical University /ID# 271931
-
-
Heilongjiang
-
Harbin, Heilongjiang, Porcelana, 150081
- Reclutamiento
- Harbin Medical University Cancer Hospital /ID# 271665
-
-
Henan
-
Zhengzhou, Henan, Porcelana, 450008
- Reclutamiento
- Henan Cancer Hospital /ID# 271927
-
-
Hubei
-
Wuhan, Hubei, Porcelana, 430022
- Reclutamiento
- Union Hospital - Tongji Medical College /ID# 271668
-
-
Jiangxi
-
Nanchang, Jiangxi, Porcelana, 330006
- Reclutamiento
- The First Affiliated Hospital of Nanchang University /ID# 271666
-
-
Shaanxi
-
Xi'an, Shaanxi, Porcelana, 710061
- Reclutamiento
- The First Affiliated Hospital of Xi'an Jiaotong University /ID# 271928
-
-
Shandong
-
Linyi, Shandong, Porcelana, 276001
- Reclutamiento
- LinYi Cancer Hospital /ID# 272068
-
-
Xinjiang
-
Ürümqi, Xinjiang, Porcelana, 830011
- Reclutamiento
- Cancer Hospital Affliated to Xinjiang Medical University /ID# 271933
-
-
-
-
Beograd
-
Belgrade, Beograd, Serbia, 11000
- Reclutamiento
- Institute for Oncology and Radiology of Serbia /ID# 270561
-
Belgrade, Beograd, Serbia, 11080
- Reclutamiento
- Clinical Hospital Center - Bezanijska Kosa /ID# 270558
-
Belgrade, Beograd, Serbia, 11000
- Reclutamiento
- University Clinical Center Serbia /ID# 270808
-
Belgrade, Beograd, Serbia, 11000
- Reclutamiento
- Military Medical Academy /ID# 279873
-
-
Nisavski Okrug
-
Niš, Nisavski Okrug, Serbia, 18300
- Reclutamiento
- University Clinical Center Nis /ID# 270557
-
-
Sremski Okrug
-
Kamenitz, Sremski Okrug, Serbia, 21208
- Reclutamiento
- Institute For Pulmonary Diseases Of Vojvodina /ID# 270559
-
-
Sumadijski Okrug
-
Kragujevac, Sumadijski Okrug, Serbia, 34000
- Reclutamiento
- University Clinical Center Kragujevac /ID# 275773
-
-
-
-
Central Singapore
-
Singapore, Central Singapore, Singapur, 169611
- Reclutamiento
- National Cancer Centre Singapore /ID# 271499
-
Singapore, Central Singapore, Singapur, 119074
- Reclutamiento
- National University Hospital /ID# 271700
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Projected life expectancy of at least 12 weeks.
- Must have c-Met overexpressing non-small cell lung cancer (NSCLC) (defined as >= 25% tumor cells with 3+ staining (high [>= 50% 3+]; intermediate [>= 25% - < 50%]) as assessed by a Sponsor designated immunohistochemistry (IHC) laboratory
- Must have histologically or cytologically documented NSCLC that is locally advanced or metastatic.
- Must have a known epidermal growth factor receptor (EGFR) activating mutation status.
- Actionable alterations in genes other than EGFR are permitted.
- Must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
- Must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1.
- Must have received no more than 1 line of prior systemic cytotoxic chemotherapy in the locally advanced or metastatic setting, as stated in the protocol.
- Must have progressed on at least 1 line of prior therapy for locally advanced/metastatic NSCLC, as stated in the protocol.
Exclusion Criteria:
- Adenosquamous or neuroendocrine histology, or sarcomatoid features.
- EGFR activating mutations (e.g., EGFR Exon 19 deletions, T790M, Exon 21 L858R, or Exon 20 insertion mutations).
- Received prior c-Met-targeted antibodies, prior telisotuzumab vedotin, or prior antibody-drug conjugates either targeting c-Met or consisting of monomethylauristatin E.
- Received prior docetaxel therapy.
- Metastases to the central nervous system (CNS). Participants with CNS metastases are eligible only after adequate treatment (such as surgery or, radiotherapy, or drug therapy) is provided, as stated on the protocol.
- History of other malignancies except those stated in the protocol.
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan, as noted in the protocol.
- Unresolved clinically significant adverse event (AE) >= Grade 2 from prior anticancer therapy, except for alopecia or anemia. Participants with hormone deficiencies caused by prior anticancer therapy who are asymptomatic and on a stable dose of replacement hormone are eligible for study.
- Major surgery within 21 days prior to randomization.
- Clinically significant condition(s) including but not limited to those listed in the protocol.
- Clinically significant liver disease, including hepatitis, current alcohol abuse, or cirrhosis.
- Grade >= 2 edema or lymphedema.
- Grade >= 2 ascites or pleural effusion.
- Grade >= 2 neuropathy.
- Active uncontrolled bacterial or viral infection.
- Active corneal disorder.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Telisotuzumab Vedotin Dose A
Participants will receive telisotuzumab vedotin dose A, as part of the 3 year study duration. |
Intravenous (IV) Infusion
Otros nombres:
|
|
Experimental: Telisotuzumab Vedotin Dose B
Participants will receive telisotuzumab vedotin dose B, as part of the 3 year study duration. |
Intravenous (IV) Infusion
Otros nombres:
|
|
Experimental: Telisotuzumab Vedotin Dose C
Participants will receive telisotuzumab vedotin dose C, as part of the 3 year study duration. |
Intravenous (IV) Infusion
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Percentage of Participants with Treatment-Emergent Adverse Events (AE)s (Any-grade and Grade >= 2)
Periodo de tiempo: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Interstitial Lung Disease (ILD)
Periodo de tiempo: Up to Approximately 3 Years
|
ILD is defined by ILD standardized MedDRA query (SMQ) (broad) per investigator and determined per adjudication (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Peripheral Neuropathy
Periodo de tiempo: Up to Approximately 3 Years
|
Peripheral neuropathy is defined by peripheral neuropathy SMQ (narrow) (any-grade and Grade >= 2) |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent Ocular Surface Disorders
Periodo de tiempo: Up to Approximately 3 Years
|
Treatment-emergent ocular surface disorders defined by corneal epitheliopathy company MedDRA query (CMQ) (any-grade and Grade >= 2). |
Up to Approximately 3 Years
|
|
Percentage of Participants with Treatment-Emergent AEs Leading to Study Drug Discontinuation
Periodo de tiempo: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Percentage of Participants with Grade 5 Treatment-Emergent AEs
Periodo de tiempo: Up to Approximately 3 Years
|
An AE is defined as any untoward medical occurrence, inappropriate participant management decision, unintended disease or injury or any untoward clinical signs (including an abnormal laboratory finding) in participants, users or other persons whether or not related to the investigational medical device. |
Up to Approximately 3 Years
|
|
Objective Response (OR) by Blinded Independent Central Review (BICR)
Periodo de tiempo: Up to Approximately 3 Years
|
OR will be defined as achieving confirmed complete response (CR) or confirmed partial response (PR) based on response evaluation criteria in solid tumors (RECIST), version 1.1. |
Up to Approximately 3 Years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Concentrations of Telisotuzumab Vedotin Conjugate in Serum
Periodo de tiempo: Up to 26 Weeks
|
Concentrations of telisotuzumab vedotin conjugate in serum. |
Up to 26 Weeks
|
|
Concentrations of Monomethylauristatin E (MMAE) Payload in Plasma
Periodo de tiempo: Up to 26 Weeks
|
Concentrations of MMAE payload in plasma. |
Up to 26 Weeks
|
|
Percentage of Participants with Antidrug Antibodies (ADAs) of Telisotuzumab Vedotin
Periodo de tiempo: Up to 26 Weeks
|
Percentage of participants with ADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Percentage of Participants with Neutralizing Antidrug Antibodies (nADAs) of Telisotuzumab Vedotin
Periodo de tiempo: Up to 26 Weeks
|
Percentage of participants with nADAs of telisotuzumab vedotin. |
Up to 26 Weeks
|
|
Change in Selected items of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Periodo de tiempo: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The PRO-CTCAE is a patient-reported outcome measurement system developed to assess symptomatic toxicity in patients participating in cancer clinical trials. PRO-CTCAE includes 124 items representing 78 symptomatic toxicities drawn from the Common Terminology Criteria for Adverse Events (CTCAE). PRO-CTCAE items evaluate the symptom attributes of frequency, severity, interference, amount, presence/absence. All questions employ a 7-day recall period and are scored from 0 to 4 (or 0/1 for absent/present). |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Change in GP5 item of the Functional Assessment of Cancer Therapy-General (FACT-G)
Periodo de tiempo: Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
The GP5 item ("I am bothered by side effects of treatment") of FACT-G is used to assess overall treatment tolerability in patients by assessing the overall side effect impact on participants. |
Cycle 1: Day 1, Day 8, Cycle 2 D1 and D1 of Every Even Cycle Thereafter, Through 3 Years
|
|
Duration of Response (DoR) by BICR
Periodo de tiempo: Up to Approximately 3 Years
|
DoR is defined for confirmed responders as the time from the participants' initial response (CR or PR) to the first occurrence of radiographic progression per RECIST v1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Progression-Free Survival (PFS) by BICR
Periodo de tiempo: Up to Approximately 3 Years
|
PFS will be defined as the time from randomization to the first occurrence of radiographic progression based on RECIST version 1.1 or death from any cause. |
Up to Approximately 3 Years
|
|
Overall Survival (OS)
Periodo de tiempo: Up to Approximately 3 Years
|
OS will be defined as the time from randomization to death from any cause. |
Up to Approximately 3 Years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: ABBVIE INC., AbbVie
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- M25-274
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Marco de tiempo para compartir IPD
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Criterios de acceso compartido de IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .